Parkman Healthcare Partners’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History

Parkman Healthcare Partners’s Portfolio DCPH Stock Details DCPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-729,230	Closed	-$11.5M	–	111
2024 Q1	$11.5M	Buy	729,230 +168,205	+30%	+$2.59M	1.41%	26
2023 Q4	$9.05M	Sell	561,025 -36,378	-6%	-$464K	1.27%	29
2023 Q3	$7.6M	Buy	597,403 +24,164	+4%	+$333K	1.39%	23
2023 Q2	$8.07M	Buy	573,239 +81,467	+17%	+$1.17M	1.4%	24
2023 Q1	$7.6M	Buy	491,772 +146,852	+43%	+$2.45M	1.65%	24
2022 Q4	$5.65M	Buy	344,920 +43,028	+14%	+$700K	1.51%	21
2022 Q3	$5.58M	Buy	+301,892	New	+$4.74M	1.59%	20

Other funds holding DCPH

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Parkman Healthcare Partners's DCPH Position: Q2 2024 in Review

Parkman Healthcare Partners sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q2 2024, closing a stake of 729,230 shares — an estimated $11.5M sold.

Parkman Healthcare Partners first reported a position in DCPH in Q3 2022 and held it in 7 quarters. The position peaked at $11.5M in Q1 2024. 1 fund tracked by Wall St. Rank holds DCPH as of Q2 2024.

Parkman Healthcare Partners reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Parkman Healthcare Partners sold 729,230 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $11.5M.
Parkman Healthcare Partners first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q3 2022 and held it in 7 quarters.
Parkman Healthcare Partners's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $11.5M in Q1 2024.
1 fund tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q2 2024.

Based on Parkman Healthcare Partners's 13F filing for Q2 2024, filed 14 Aug 2024.